No­var­tis bet $6B on the idea — now Ver­sant, ven­Bio have $45M to birth a plat­form play for ra­dio­phar­ma­ceu­ti­cals

Back in 2017, in the wake of back-to-back set­backs and a re­or­ga­ni­za­tion, a strug­gling lit­tle biotech named En­do­cyte com­plet­ed a $12 mil­lion li­cens­ing deal that would ul­ti­mate­ly put it on a path to­ward a $2.1 bil­lion buy­out.

As it turned out, Ver­sant Ven­tures was al­so eye­ing that very same drug out of Ger­many: PS­MA-617, a ra­di­oli­gand ther­a­peu­tic for cas­tra­tion-re­sis­tant prostate can­cer.

“We ac­tu­al­ly put a term sheet out on that as­set be­cause we just thought the ef­fi­ca­cy da­ta were so pro­found there,” man­ag­ing di­rec­tor Jer­el Davis told End­points News, re­fer­ring to a drug that reg­is­tered a pro­gres­sion-free sur­vival rate of 7.6 months among PS­MA-pos­i­tive pa­tients, with one co­hort hit­ting an over­all sur­vival rate of 13.5 months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER